EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

30% Supramolecular Salicylic Acid Improved Symptoms and Skin Barrier in Papulopustular Rosacea

Zihan Wang, Yutong Wu, Fatemeh Nozzari Varkani, Xian Su, Ziping Yang, Xinghua Gao iD, Li Zhang iD

Journal of Cosmetic Dermatology · 2025

DOI: 10.1111/jocd.70046 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Cosmetic Dermatology, 2025. Verfasst von Zihan Wang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning, China. Hauptthemen laut MEDLINE: Rosacea, Salicylic Acid, Dermatologic Agents. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Rosacea is a chronic skin condition that affects millions of people worldwide, and its management continues to pose a significant challenge in dermatology.

Aim

In this study, we investigated the efficacy and safety of 30% supramolecular salicylic acid (SSA) as a treatment for papulopustular rosacea, with a particular focus on improving skin lesions, reducing persistent erythema, and enhancing skin barrier function.

Methods

Thirty‐four patients diagnosed with papulopustular rosacea were randomly divided into an experimental group treated with 30% SSA and a control group receiving a placebo. Clinical outcomes were evaluated based on lesion reduction rates, investigator severity assessment (ISA) scores, VISIA red area scores, and skin barrier, including trans‐epidermal water loss (TEWL), sebum levels, stratum corneum hydration, and pH values.

Results

A total of 34 patients were collected for both the experimental and control groups, with no statistical differences in age or disease severity between the groups ( p > 0.05). The effective rate was 68.75% in the experimental group ( p < 0.01). After treatment, the ISA score was 1.75 ± 0.68 in the experimental group and 2.40 ± 0.83 in the control group, indicating significant improvement ( p < 0.05). The improvement rate of the VISIA redness score was 25.1% in the experimental group ( p < 0.01). Among the 17 patients who underwent skin barrier function testing. Skin hydration significantly improved on left cheek ( p < 0.05), right cheek ( p < 0.01), and nose ( p < 0.05) after 30% SSA treatment in experimental group. Sebum levels were significantly reduced on both cheeks and forehead ( p < 0.05). No statistical differences were observed in other locations. Skin TEWL and pH value showed no changes.

Conclusion

30% SSA reduced papules and pustules in rosacea, improved persistent erythema, and enhanced stratum corneum hydration in the 30% SSA‐treated group compared to the placebo group. No significant differences were observed in TEWL and skin pH values between the two groups. Our findings suggest that 30% SSA is an effective and safe option for managing papulopustular rosacea, offering a well‐tolerated alternative to traditional treatments.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RosaceaSalicylic AcidDermatologic AgentsHumansFemaleMaleAdultMiddle AgedWater Loss, InsensibleTreatment OutcomeSebumSeverity of Illness IndexAdministration, CutaneousYoung AdultDouble-Blind MethodHydrogen-Ion ConcentrationErythemaSkin

Stichwörter der Autor:innen

chemical peelingpapulopustular rosaceaskin barriersupramolecular salicylic acid

Substanzen

Salicylic AcidDermatologic Agents

Autor:innen und Institutionen

  • Department of Dermatology, The First Hospital of China Medical University, Shenyang, Liaoning, China.
  • Department of Medical Cosmetic, Shenzhen Nanshan People's Hospital, Shenzhen, Guangdong, China.
  • Department of Dermatology, Children's Hospital of Soochow University, Suzhou, Jiangsu, China.

ORCID-Profile: Xinghua Gao, Li Zhang

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Wang, Z., Wu, Y., Varkani, F. N., Su, X., Yang, Z., Gao, X., & Zhang, L. (2025). 30% Supramolecular Salicylic Acid Improved Symptoms and Skin Barrier in Papulopustular Rosacea. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.70046

Vancouver

Wang Z, Wu Y, Varkani FN, Su X, Yang Z, Gao X, et al. 30% Supramolecular Salicylic Acid Improved Symptoms and Skin Barrier in Papulopustular Rosacea. Journal of Cosmetic Dermatology. 2025. doi:10.1111/jocd.70046

BibTeX
@article{Wang2025,
  author = {Wang, Zihan and Wu, Yutong and Varkani, Fatemeh Nozzari and Su, Xian and Yang, Ziping and Gao, Xinghua and Zhang, Li},
  title = {30% Supramolecular Salicylic Acid Improved Symptoms and Skin Barrier in Papulopustular Rosacea},
  journal = {Journal of Cosmetic Dermatology},
  year = {2025},
  doi = {10.1111/jocd.70046}
}
Kostenlos starten →